Related Experiment Video
Updated: Jun 11, 2026
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
Intravenous proton pump inhibitor uses for stress ulcer prophylaxis in the critically ill: a single-center study in
Saba Noureen1, Waseem Ullah1, Mahnoor Asad1
1Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, 44000 Islamabad, Pakistan.
Introduction:
Irrational use of intravenous (IV) proton pump inhibitors (PPIs) for stress ulcer prophylaxis (SUP) in critically ill patients increases the risk of adverse drug reactions (ADRs), and may lead to longer stays in the intensive care unit (ICU).
Methodology:
A single-center, retrospective, observational study was conducted to assess the practices with prescribing IV SUP in critically ill adult patients treated at ICUs between January 2020-December 2022. Data was collected from electronic medical records, using a pre-designed checklist. Appropriateness of SUP administration was determined using the American Society of Health-System Pharmacists (ASHP) recommendations.
Results:
Medical records of 1076 patients were analyzed; majority of patients (80.9%; n = 873) received IV SUP during their ICU stay, with the most commonly prescribed drug being omeprazole (99.2%). 75.5% of patients had no major or minor risk factors based on ASHP guidelines. The rationale of SUP was deemed appropriate in 51.7% of cases. Among patients treated at specific ICU wards, male patients were less likely (OR: 0.587 [95% CI: 0.345-0.998]; p = 0.048), while ventilated patients were more likely (OR: 2.525 [95% CI: 1.219-5.233]; p = 0.013) to receive SUP. Furthermore, ≥10 days of hospital stay corresponded to notable increase (OR: 4.076 [95% CI: 0.870-19.098]; p = 0.086) in the probability of receiving SUP.
Conclusions:
The results may provide a basis for developing protocols related to acid-suppressive therapy in critically ill adults, calling for heightened awareness and tailored interventions to optimize pharmacological care in ICU settings.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:25Peptic Ulcer Disease I: Introduction